Magnetic Resonance-Guided Adaptive Radiotherapy (MRgART) Using an Integrated Magnetic Resonance Linear Accelerator (MRL)

Study Overview
=================
Brief Summary
-----------------
This study is being done to help further understand how MR-guided adaptive RT in conjunction with the Integrated Magnetic Resonance Linear Accelerator (MRL) can improve patient outcomes. This study will include participants who will be receiving radiotherapy using the MRL machine to target their cancer more precisely. Participants will be asked to have a few extra MR scans taken during their RT planning and to complete a few quality of life questionnaires.

Official Title
-----------------
Magnetic Resonance-Guided Adaptive Radiotherapy (MRgART) Using an Integrated Magnetic Resonance Linear Accelerator (MRL)

Conditions
-----------------
Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients 18 years or older with a diagnosis of cancer, regardless of clinical site or stage Planned to receive a course of MR-guided adaptive RT using the MRL Ability to provide informed consent Exclusion Criteria: Patients under 18 years old

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Local, regional and distant tumor control rates | Refine our understanding of clinical scenarios where MRgART with the MRL improves patient outcomes and translate this new knowledge and new treatment approach to widespread clinical practice through the development and validation of efficient, cost-effective treatment processes. | Up to 5 years post-radiotherapy | 
| Disease-free and overall survival rates | Refine our understanding of clinical scenarios where MRgART with the MRL improves patient outcomes and translate this new knowledge and new treatment approach to widespread clinical practice through the development and validation of efficient, cost-effective treatment processes. | Up to 5 years post-radiotherapy | 
| Complication rates measured using the Common Toxicity Criteria for Adverse Events | Refine our understanding of clinical scenarios where MRgART with the MRL improves patient outcomes and translate this new knowledge and new treatment approach to widespread clinical practice through the development and validation of efficient, cost-effective treatment processes. | Within 3 months of completing treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient experience and anxiety related to MR imaging and adaptive RT with the MR | Evaluate the patient experience during adaptive RT with the MRL using the Magnetic Resonance Imaging-Anxiety Questionnaire (MRI-AQ) which measures patient anxiety and tolerability of MR-related procedures | Immediately after first MRL treatment visit | 
| Patient experience and anxiety related to MR imaging and adaptive RT with the MR | Evaluate the patient experience during adaptive RT with the MRL using the EORTC satisfaction with cancer care core questionnaire (EORTC PATSAT-C33) and specific complementary outpatient module (EORTC OUT-PATSAT7) | Immediately after last MRL treatment visit | 
| Patient experience and anxiety related to MR imaging and adaptive RT with the MR | Evaluate the patient experience during adaptive RT with the MRL using -The EORTC QLQ C30 quality of life questionnaire | d prior to starting treatment with the MRL, immediately after the last MRL treatment, at the first follow-up visit and annually thereafter during follow-up (up to 5 years post treatment) | 
| Patient experience and anxiety related to MR imaging and adaptive RT with the MR | Evaluate the patient experience during adaptive RT with the MRL using complete the Edmonton Symptom Assessment Scale revised version (ESAS-r) | each ambulatory care and radiation treatment review clinic visit (up to 5 years post treatment) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MRL